Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Caroline Litchfield net worth and biography

Caroline Litchfield Biography and Net Worth

CFO of Merck & Co., Inc.

Caroline Litchfield is executive vice president and chief financial officer for Merck, responsible for the company’s finance, procurement and real estate operations.

Prior to this role, Caroline served as the company’s treasurer, a position that included responsibility for treasury, tax and investor relations. From 2014 to 2018, Caroline led finance for Human Health, the company’s largest business, overseeing financial operations and reporting in approximately 100 markets.

Previously, Caroline was the vice president and finance lead for the company’s Emerging Markets region when it was established in 2009 following the merger of Merck and Schering-Plough and was instrumental in integrating the two companies. She joined Merck in 1990 in its U.K. business and has held a wide range of positions of increasing responsibility in the company’s country, regional and global finance functions.

Caroline received her Bachelor of Science degree in Mathematics from the University of Leicester and is a fellow of the Chartered Institute of Management Accountants.

How old is Caroline Litchfield?: Ms. Litchfield is currently 55 years old. There are 6 older executives and no younger executives at Merck & Co., Inc.. The oldest executive at Merck & Co., Inc. is Dr. Dean Y. Li M.D., Ph.D., Executive VP & President of Merck Research Laboratories, who is 62 years old. Learn More on Caroline Litchfield's age.
How do I contact Caroline Litchfield?: The corporate mailing address for Ms. Litchfield and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Caroline Litchfield's contact information.
Has Caroline Litchfield been buying or selling shares of Merck & Co., Inc.?: Caroline Litchfield has not been actively trading shares of Merck & Co., Inc. over the course of the past ninety days. Most recently, Caroline Litchfield sold 18,335 shares of the business's stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $91.00, for a transaction totalling $1,668,485.00. Learn More on Caroline Litchfield's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Caroline Litchfield Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/4/2021	Sell	18,335	$91.00	$1,668,485.00

Caroline Litchfield Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $125.78

$124.89

$126.12

50 Day Range

MA: $126.18

$120.54

$131.95

2 Week Range

Now: $125.78

$99.14

$133.10

Volume

8,377,080 shs

Average Volume

6,808,079 shs

Market Capitalization

$318.60 billion

P/E Ratio

898.43

Dividend Yield

2.46%

Beta

0.38